Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The SELECT trial builds on these results, showing that once-weekly semaglutide resulted in a 20% reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with pre-existing cardiovascular disease and BMI 27kg/m 2
Malaguarnera M, Gargante MP, Cristaldi E, Colonna V, Messano M, Koverech A et al
Sources Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY
This starts to approach the upper range of a 100-unit syringe, so accuracy matters
They are not approved for human consumption, clinical use, or diagnostic purposes
US$ 27.08
US$ 23.15
US$ 23.80
US$ 22.98
US$ 25.67
US$ 25.66
